A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism
Abstract Interleukin-2 (IL-2) has been shown to suppress immune pathologies by
preferentially expanding regulatory T cells (Tregs). However, this therapy has been limited …
preferentially expanding regulatory T cells (Tregs). However, this therapy has been limited …
Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species
U Karakus, D Sahin, PRE Mittl, P Mooij… - Science translational …, 2020 - science.org
Stimulation of regulatory T (Treg) cells holds great promise for the treatment of autoimmune,
chronic inflammatory, and certain metabolic diseases. Recent clinical trials with low-dose …
chronic inflammatory, and certain metabolic diseases. Recent clinical trials with low-dose …
IL-2/CD25: a long-acting fusion protein that promotes immune tolerance by selectively targeting the IL-2 receptor on regulatory T cells
Low-dose IL-2 represents an immunotherapy to selectively expand regulatory T cells (Tregs)
to promote tolerance in patients with autoimmunity. In this article, we show that a fusion …
to promote tolerance in patients with autoimmunity. In this article, we show that a fusion …
Immune modulation: IL-1, master mediator or initiator of inflammation
KHG Mills, A Dunne - Nature medicine, 2009 - nature.com
There are many ways to modulate the immune response in a therapeutic setting. Drugs that
target the proinflammatory mediator IL-1, for instance, can counteract disease in certain …
target the proinflammatory mediator IL-1, for instance, can counteract disease in certain …
[HTML][HTML] Engineering IL-2 to give new life to T cell immunotherapy
WW Overwijk, MA Tagliaferri… - Annual review of …, 2021 - annualreviews.org
Interleukin-2 (IL-2) is integral to immune system regulation. Its opposing immunostimulatory
and immunosuppressive actions make it an attractive therapeutic target for cancer and …
and immunosuppressive actions make it an attractive therapeutic target for cancer and …
[HTML][HTML] Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection
Summary Low-dose human interleukin-2 (hIL-2) treatment is used clinically to treat
autoimmune disorders due to the cytokine's preferential expansion of immunosuppressive …
autoimmune disorders due to the cytokine's preferential expansion of immunosuppressive …
[HTML][HTML] Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms
Summary Interleukin-2 (IL-2) is a pleiotropic cytokine that regulates immune cell
homeostasis and has been used to treat a range of disorders including cancer and …
homeostasis and has been used to treat a range of disorders including cancer and …
Engineering IL-2 for immunotherapy of autoimmunity and cancer
R Hernandez, J Põder, KM LaPorte… - Nature Reviews …, 2022 - nature.com
Preclinical studies of the T cell growth factor activity of IL-2 resulted in this cytokine
becoming the first immunotherapy to be approved nearly 30 years ago by the US Food and …
becoming the first immunotherapy to be approved nearly 30 years ago by the US Food and …
Engineering a single-agent cytokine/antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy
IL-2 has been used to treat diseases ranging from cancer to autoimmune disorders, but its
concurrent immunostimulatory and immunosuppressive effects hinder efficacy. IL-2 …
concurrent immunostimulatory and immunosuppressive effects hinder efficacy. IL-2 …
Application of IL-2 therapy to target T regulatory cell function
EM Shevach - Trends in immunology, 2012 - cell.com
Interleukin-2 (IL-2) was originally discovered as a growth factor for activated T cells in vitro.
IL-2 promotes CD8+ T cell growth and differentiation in vivo, but has little effect on CD4+ T …
IL-2 promotes CD8+ T cell growth and differentiation in vivo, but has little effect on CD4+ T …